PL3849596T3 - Kompozycje do zastosowania w leczeniu chorób oczu zależnych od końcowych produktów zaawansowanej glikacji - Google Patents
Kompozycje do zastosowania w leczeniu chorób oczu zależnych od końcowych produktów zaawansowanej glikacjiInfo
- Publication number
- PL3849596T3 PL3849596T3 PL19779370.6T PL19779370T PL3849596T3 PL 3849596 T3 PL3849596 T3 PL 3849596T3 PL 19779370 T PL19779370 T PL 19779370T PL 3849596 T3 PL3849596 T3 PL 3849596T3
- Authority
- PL
- Poland
- Prior art keywords
- compositions
- end products
- ocular diseases
- advanced glycation
- glycation end
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/45—Transferases (2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/01—Phosphotransferases with an alcohol group as acceptor (2.7.1)
- C12Y207/01171—Protein-fructosamine 3-kinase (2.7.1.171)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01036—Hyaluronoglucuronidase (3.2.1.36)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Ophthalmology & Optometry (AREA)
- Inorganic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Emergency Medicine (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18194420 | 2018-09-14 | ||
| EP19184875 | 2019-07-08 | ||
| PCT/EP2019/074058 WO2020053188A1 (en) | 2018-09-14 | 2019-09-10 | Compositions for use to treat advanced glycation end products-dependent ocular diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3849596T3 true PL3849596T3 (pl) | 2024-06-10 |
Family
ID=68084757
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL19779370.6T PL3849596T3 (pl) | 2018-09-14 | 2019-09-10 | Kompozycje do zastosowania w leczeniu chorób oczu zależnych od końcowych produktów zaawansowanej glikacji |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US12171811B2 (pl) |
| EP (1) | EP3849596B1 (pl) |
| JP (1) | JP7401929B2 (pl) |
| CN (1) | CN112739373B (pl) |
| AU (1) | AU2019337382B2 (pl) |
| CA (1) | CA3110040A1 (pl) |
| ES (1) | ES2973319T3 (pl) |
| PL (1) | PL3849596T3 (pl) |
| WO (1) | WO2020053188A1 (pl) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3210369A1 (en) * | 2021-03-08 | 2022-09-15 | Universiteit Gent | Treatment of eye diseases with fructosyl-amino acid oxidase |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100297046A1 (en) | 2006-03-31 | 2010-11-25 | Dynamis Therapeutics, Inc. | Compositions and Methods Related to Fructosamine-3-Kinase Inhibitors |
| CA2781309A1 (en) * | 2009-12-04 | 2011-06-09 | Euclid Systems Corporation | Composition and methods for the prevention and treatment of macular degeneration, diabetic retinopathy, and diabetic macular edema |
| JP7213891B2 (ja) | 2018-01-30 | 2023-01-27 | ユニベルシテイト ゲント | 白内障を処置するのに使用するための組成物 |
-
2019
- 2019-09-10 US US17/269,234 patent/US12171811B2/en active Active
- 2019-09-10 WO PCT/EP2019/074058 patent/WO2020053188A1/en not_active Ceased
- 2019-09-10 CA CA3110040A patent/CA3110040A1/en active Pending
- 2019-09-10 AU AU2019337382A patent/AU2019337382B2/en active Active
- 2019-09-10 CN CN201980059516.4A patent/CN112739373B/zh active Active
- 2019-09-10 PL PL19779370.6T patent/PL3849596T3/pl unknown
- 2019-09-10 ES ES19779370T patent/ES2973319T3/es active Active
- 2019-09-10 EP EP19779370.6A patent/EP3849596B1/en active Active
- 2019-09-10 JP JP2021514040A patent/JP7401929B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP3849596B1 (en) | 2023-12-20 |
| CN112739373A (zh) | 2021-04-30 |
| JP7401929B2 (ja) | 2023-12-20 |
| WO2020053188A9 (en) | 2020-05-22 |
| US12171811B2 (en) | 2024-12-24 |
| CA3110040A1 (en) | 2020-03-19 |
| WO2020053188A1 (en) | 2020-03-19 |
| AU2019337382B2 (en) | 2024-10-17 |
| EP3849596C0 (en) | 2023-12-20 |
| AU2019337382A1 (en) | 2021-03-18 |
| ES2973319T3 (es) | 2024-06-19 |
| US20210322523A1 (en) | 2021-10-21 |
| JP2022500429A (ja) | 2022-01-04 |
| EP3849596A1 (en) | 2021-07-21 |
| CN112739373B (zh) | 2024-07-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL267997A (en) | Preparations, formulations and methods for treating eye diseases | |
| IL259123B (en) | The compositions for applying to the skin | |
| ZA202006610B (en) | Compositions for the treatment of skin conditions | |
| EP3263132A4 (en) | Composition for treating il-6-related diseases | |
| IL275321A (en) | Treatment of diseases associated with the expression of DUX4 | |
| EP3169784A4 (en) | Organic compositions to treat apoc3-related diseases | |
| ZA202007055B (en) | Compositions for the treatment of skin conditions | |
| IL258032A (en) | Compounds and preparations for the treatment of ocular disorders | |
| IL261774B (en) | Preparations for the treatment of skin problems | |
| EP3744347A4 (en) | COMPOSITION FOR USE IN THE TREATMENT OF SKIN DISEASES | |
| EP3160460A4 (en) | Ketobutyrate compounds and compositions for treating age-related symptoms and diseases | |
| PL3493823T4 (pl) | Składnik na bazie postbiotyki do leczenia zapalenia oka | |
| SG11202008959RA (en) | Composition for improving skin conditions | |
| IL280952A (en) | Methods and drug compounds for the treatment of ophthalmic diseases | |
| PL3746114T3 (pl) | Kompozycje do zastosowania w leczeniu zaćmy | |
| ZA202003944B (en) | Ophthalmic topical composition comprising dobesilic acid for treating diseases of the posterior segment of the eye | |
| EP3265103A4 (en) | Compositions and methods for treating ocular diseases | |
| EP3813872A4 (en) | COMPOSITIONS FOR THE TREATMENT OF SKIN CONDITIONS | |
| EP3215222A4 (en) | Methods of treating huntington's disease using cysteamine compositions | |
| PL3849596T3 (pl) | Kompozycje do zastosowania w leczeniu chorób oczu zależnych od końcowych produktów zaawansowanej glikacji | |
| PL3773641T3 (pl) | Kompozycje farmaceutyczne do stosowania miejscowego w leczeniu dolegliwości skórnych | |
| IL252543A0 (en) | Compounds for the treatment of degenerative retinal tissues | |
| GB201601456D0 (en) | Improvements relating to retinal treatment | |
| GB201908076D0 (en) | Skin treatment composition | |
| ZA201805926B (en) | Synergistic fungicidal composition for controlling plant diseases |